Ultragenyx Fell 72%-But Is RARE Finally Out of Overvaluation Trouble?

A 72% drop changed the tone, not the valuation problem

Ultragenyx has declined 72.1% over the past 5 years, but the stock still does not look like an obvious bargain. Current valuation checks suggest a name that is neither clearly cheap nor clearly expensive. The selloff likely washed out some optimism and overreaction, yet it did not remove the need for execution proof.

Why the next update matters

Ultragenyx set May 5, 2026 to discuss its first-quarter results and corporate update. That timing matters because shares have also lost about 13.6% in that time frame leading into the next earnings check. The stock looks less like a high-flying growth story than it did a year ago, but it still needs to prove that the decline has absorbed the obvious execution concerns.

What the reset did not solve

Management reaffirmed full year 2026 total revenue guidance of $730 million to $760 million, which helps preserve credibility. But the same quarter also produced total revenue in the first quarter of 2026 was $136 million, below consensus, while Crysvita revenue of $93 million reflected seasonality and regional ordering patterns. The good news is that expectations reset lower. The hard part-commercial follow-through and regulatory execution-has not changed.

The market is still judging one weak quarter as a story test

When RARE reported Q1 revenue of $136 million against $161 million expected, the reaction went beyond the headline miss. Investors also focused on Crysvita revenue of $93 million, down 10% year over year, because a soft quarter in the flagship product can look like the start of a broader commercial problem.

Expectations had already fallen

That sensitivity helps explain why the stock responded so sharply when later results came in better than feared. Shares had previously closed at $25.81 and then opened at $28.48 after the company reported better-than-expected quarterly earnings. In other words, part of the market had already priced in a worse outcome.

That does not make the stock safe. It means expectations can swing hard in both directions. If Ultragenyx can hold its 2026 guidance and show steadier commercial execution, the post-earnings drop may have gone far enough. If not, the market may treat the first-quarter miss as a pattern rather than a setback.

Pipeline milestones, not chart depth, are the real value test

After the reset and the company's mixed valuation read, Ultragenyx no longer has much room to rely on long-term potential alone. The market now needs evidence that the pipeline can turn into de-risked milestones.

Management has two BLAs under review, said the Angelman Phase 3 readout coming soon, and expects Phase 3 data expected in the second half of 2026. That creates a dense catalyst window. How those milestones land will matter more than whether the stock looks oversold on a chart.

What would strengthen the story

• BLA reviews advance without major setbacks.
• The Angelman program keeps the market focused on near-term data rather than long-term hope.
• The company stays on course toward profitability in 2027.

Where the risks still matter

• BLA timelines or expectations run into delays.
• Phase 3 results do not support the longer-term signal investors are leaning on.
• Pipeline value fails to convert into realized revenue if launches or approvals take longer than expected.

That last point is important: approval would broaden revenue sources and reduce reliance on one main commercial engine, but pipeline value is still contingent until that happens.

Competitive pressure is real, even if it is not the whole story

Investors also need to keep competition in view. Agamree is already approved in DMD as an alternative treatment choice with efficacy comparable to traditional corticosteroid options. That does not mean every Ultragenyx asset faces the same competitive headwind, but it does show that at least part of the broader neuromuscular landscape is becoming more populated.

So has Ultragenyx fallen far enough?

The key question is not whether RARE looks cheap by itself. It is whether the market has stopped treating the company like a damaged story and started treating it as an execution case that can support the current price. After a mixed valuation read, that comes down to three things:

• the existing revenue base
• the path to profitability in 2027
• progress from two BLAs under review and the upcoming Angelman data readthrough

That is why the May 5 financial results and corporate update matters so much. The stock does not have to look inexpensive for the selloff to have gone far enough. It only has to stop pricing in clear execution failure.